NE Regional Tile

NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

Saturday, May 4

7:30am – 3:30pm 

Earn AMA PRA Category 1 Credits,™ Continuing Nursing Education (ANCC), and MOC accreditation

Register Now

Location

Renaissance Providence Downtown Hotel
5 Ave of the Arts, Providence, RI 02903

Providers

Jointly Provided by Yale Cancer Center and Smilow Cancer Hospital, Dana-Farber Cancer Institute, and the North American Neuroendocrine Tumor Society

    ynhhs_sch_ycc_hor_clr.jpeg

dana-farber-logo-png_4x.png

Course Directors

Pamela L. Kunz, MD, Yale School of Medicine

Jennifer Chan, MD, MPH, Dana-Farber Cancer Institute

Overview

Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years, there was great variability in terms of treatment. The diagnosis, treatment, and management of NETs are time-consuming, complex, and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
  • Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
  • Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
  • Recognize the clinical features associated with carcinoid syndrome
  • Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
  • Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors

Program

7:30am - 8:00am
8:00am - 8:10am
Registration and Breakfast
Welcome and Opening Remarks
    • Jennifer Chan, MD, MPH, Clinical Director, Gastrointestinal Cancer Center, Director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School
    • Pamela L. Kunz, MD, Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Chief, GI Medical Oncology, Yale School of Medicine
8:10am - 9:10am
Work-up and Diagnostics
    • Epidemiology of Neuroendocrine Neoplasms
      Simron Singh, MD, MPH, Associate Professor, University of Toronto; Provincial Head, Person-Centered Care, Cancer Care Ontario; Medical Oncologist, Sunnybrook Odette Cancer Center/Susan Leslie Clinic for Neuroendocrine Cancer
    • Pathology of Neuroendocrine Neoplasms
      Marie Robert, MD, Professor of Pathology and of Medicine, Yale School of Medicine
    • Imaging of Neuroendocrine Neoplasms
      Gabriela Spilberg, MD, Assistant Professor; Director, Theranostics and Clinical Trials for the Section of Nuclear Medicine, Radiology and Biomedical Imaging, Yale School of Medicine
    • Work-up and diagnosis of functional Neuroendocrine Tumor Syndromes
      Jaydira Del Rivero, MD, Physician Scientist, Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health
    • Moderator: Rebecca Vanasse-Passas, MD, Assistant Professor of Medicine, Yale School of Medicine
9:10am - 9:40am
Break
9:40am - 11:10am
GEPNETs
    • Topic: Hormone control and management of functional Neuroendocrine Tumor Syndromes
      Hussein Assi, MD, Assistant Professor of Medicine, Boston University Chobanian & Avedisian School of Medicine; GI Medical Oncologist, Boston Medical Center (BMC)
    • Systemic Treatment - Medical therapy options for metastatic GEP-NET
      Pamela L. Kunz, MD, Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Chief, GI Medical Oncology, Yale School of Medicine
    • Systemic Treatment - Peptide receptor radionuclide therapy for metastatic GEP-NET
      Matthew Robertson, MD, Nuclear Medicine Physician, Dana-Farber Cancer Institute; Instructor, Harvard Medical School
    • Debulking Strategies for Metastatic GEP-NET - Surgical options
      Thomas E. Clancy, MD, FACS, Co-Director, Pancreas and Biliary Tumor Center, Dana-Farber Cancer Institute; Assistant Professor of Surgery, Harvard Medical School
    • Debulking Strategies for Metastatic GEP-NET - Interventional radiology options
      Matthew P. Schenker, MD, Chief, Division of Angiography and Interventional Radiology, Brigham and Women's Hospital; Assistant Professor, Harvard Medical School
    • Moderator: Matthew C. Dugan, DO, Associate Instructor, Tufts University School of Medicine, at the University of Vermont, and the University of New England
11:10am - 11:30am
Poorly Differentiated Neuroendocrine Carcinomas
    • NEC
      Jennifer Chan, MD, MPH, Clinical Director, Gastrointestinal Cancer Center, Director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School
11:30am - 12:30pm
Lunch
12:30pm - 1:30pm
Lung NETs
    • Medical therapy options for metastatic Lung NET
      Robert Ramirez, DO, Associate Professor of Medicine, Division of Hematology and Oncolocy, Department of Medicine, Vanderbilt University Medical Center
    • Peptide receptor radionuclide therapy for metastatic Lung NET
      Heather Jacene, MD, Clinical Director, Nuclear Medicine/PET-CT, Dana-Farber Cancer Institute; Associate Professor of Radiology, Harvard Medical School
    • Surgical options for Lung NET
      Justin D. Blasberg, MD, MPH, FACS, Associate Professor of Surgery (Thoracic); Director of Robotic Thoracic Surgery, Yale School of Medicine
    • Moderator: Hina Khan, MD, Director, Thoracic Oncology Clinic, The Miriam Hospital
1:30pm - 2:30pm
Special Considerations
    • Carcinoid Heart Disease
      Anju Nohria, MD, Assistant Professor of Medicine, Harvard Medical School
    • Management of Small NETs
      Anil Nagar, MD, Associate Professor of Medicine (Digestive Diseases), Yale School of Medicine
    • Hereditary Neuroendocrine Tumor Syndromes and role of germline testing
      Kimberly Perez, MD, Senior Physician, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School
    • Personalized Medicine in NENs
      Thor R. Halfdanarson, MD, Professor of Oncology; Associate Professor of Medicine, Mayo Clinic
2:30pm - 3:15pm
Tumor Board
    • Moderators
      Jennifer Chan, MD, MPH, Clinical Director, Gastrointestinal Cancer Center, Director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School
      Pamela L. Kunz, MD, Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Chief, GI Medical Oncology, Yale School of Medicine
    • Case Presenters
      pNET sequence – John Kunstman, MD, MHS, FACS, Assistant Professor of Surgery, Yale School of Medicine
      GI NET sequence – Rimini A. Breakstone, MD, Assistant Professor of Medicine, Clinician Educator, Brown University
      NEC – Arvind N. Dasari, MD, MS, Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center
3:15pm - 3:30pm
Closing Remarks
    • Jennifer Chan, MD, MPH, Clinical Director, Gastrointestinal Cancer Center, Director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School
    • Pamela L. Kunz, MD, Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Chief, GI Medical Oncology, Yale School of Medicine

*Program is tentative and subject to change* 

Register Now

Accreditation

This continuing education activity is provided through collaboration between the North American Endocrine Tumor Society (NANETS) and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, and nurses. A statement of participation is available for other attendees.

Physicians, Physician Assistants, and Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians for ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation enables the participant to earn up to 5.5 Medical Knowledge only MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Use of Learner/Participant Data

Participation information will be shared with the applicable certifying board via ACCME PARS.

In order for MOC credit to be reported, evaluations must be completed prior to the close of evaluations.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and NANETS. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 5.5 hours of continuing nursing education credit.

Registration fee:

NANETS Member

$65 USD - MD, PharmD, Doctoral Level 
$35 USD - Allied Health
Complimentary - Student/Fellow/Resident

Non-Member

$95 USD - MD, PharmD, Doctoral Level 
$50 USD - Allied Health
Complimentary - Student/Fellow/Resident

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before April 19, 2024. On or after April 20, 2024, no refund will be made.

Yale School of Medicine, Dana-Farber Cancer Institute, and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.

Questions?

Please contact us with any questions.